The parties expect the transaction to close tomorrow, December 23. The filing did not divulge redemption figures, but LifeSci opened the morning of the vote at $19, so one would guess they were “manageable”.
All measures up for a vote passed by wide margins, but about 12.5% of shares voted against the combined company’s incentive plan.
LifeSci initially announced its combination with with Vincera September 29. Vincera is developing a preclinical bioconjugation platform targeting surface markers for solid tumors.
For a full list of measures on the ballot as well as vote tallies, click HERE.